Search

EB-5 Program Returns, but Some Issues Unresolved “The industry is up in arms, and investors are losing confidence,” says attorney Ronald Fieldstone, partner in the Miami office of Saul Ewing.

Washington, D.C., November 24, 2021 – Saul Ewing LLP served as counsel to Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the successful completion today of its previously announced $450 million acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The acquisition strengthens Supernus'...